Journal article
Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity
GJ Ooi, A Earnest, WW Kemp, PR Burton, C Laurie, A Majeed, N Johnson, C McLean, SK Roberts, WA Brown
International Journal of Obesity | NATURE PUBLISHING GROUP | Published : 2018
Abstract
Introduction: In obese individuals, nonalcoholic fatty liver disease (NAFLD) is common but often goes undiagnosed, and therefore untreated. The presence of significant fibrosis is a key determinant of NAFLD progression, and liver steatosis has substantial cardiovascular implications. We aimed to determine the diagnostic accuracy of common noninvasive diagnostic tests for steatosis and fibrosis in the obese. Methods: We recruited 182 severely and morbidly obese individuals undergoing bariatric surgery (age 44 ± 12 years, body mass index 45.1 ± 8.3 kg/m2). Medical history, blood tests and liver biopsy were taken on the day of surgery. Serum steatosis and fibrosis scores were calculated. In a s..
View full abstractGrants
Funding Acknowledgements
GO, PB, CL and WB report being affiliated with the Centre for Obesity Research and Education. The Centre has received funding for research purposes from Allergan and Apollo Endosurgery, the manufacturers of the LapBand T. The grant is not tied to any specific research project, and neither Allergan nor Apollo Endosurgery have control of the protocol, analysis and reporting of any studies. The Centre also receives a grant from Applied Medical towards educational programs. WB reports financial support for a bariatric surgery registry from the Commonwealth of Australia, Apollo Endosurgery, Covidien, Johnson and Johnson, Gore and Applied Medical; and a speaker's honorarium from Merck Sharpe and Dohme. These are outside of the submitted work. NJ reports speaker's honorarium from Merck Sharpe & Dohme, which is outside of the submitted work. GO reports scholarships from the National Health and Medical Research Council and the Royal Australasian College of Surgeons. WK, AE, AM, CM, SR have no other disclosures or conflicts of interest.